Iron deficiency anemia is the most common form of anemia observed in clinical practice. The infusion of intravenous iron quanhas proved to be safe and effective and to quickly lead patients to normal hemoglobin levels. Starting from the collection of healthcare resources consumption in five Italian hospitals, the economic impact of the management of patients with iron deficiency anemia in Italy on hospitals and regional health systems has been estimated considering different scenarios of utilization of ferric carboximaltose (FCM) and ferric gluconate (FG). Regional reimbursement tariffs have been used to estimate the economic burden from the perspective of the regional systems, while the cost function related to different inputs was used for the hospital perspective. Assuming a full replacement of FG by FCM, the maximum savings achievable by the Italian health system would be approximately 34 million euro. From the hospital perspective, with a single infusion of 1000 mg of FCM, at the current cost of 131,24 €, it is possible to get savings of 75% compared to 16 infusions of FG 62.5 mg each and 50% compared to 8 infusions of two vials of FG each (125 mg). In conclusion, FCM can be considered a cost-saving option, from both regional health systems and hospital point of views, as compared to the currently and widely adopted iron formulation for the treatment of patients with iron deficiency anemia in Italy.
Keywords: Iron deficiency anemia, ferric carboxymaltose, ferric gluconate, cost, budget impact.